title: CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.
abstract: The rate of long-term remissions after treatment of peripheral T cell lymphomas (PTCL) with standard CHOP-like protocols is unsatisfactory. A prospective multicenter phase II trial was initiated in untreated patients with PTCL of all International Prognostic Index-risk groups, evaluating alemtuzumab consolidation in patients with complete or good partial remission after CHO(E)P-14 induction. Twenty-nine (70.7 %) of the 41 enrolled patients received alemtuzumab consolidation (133 mg in total). The main grades 3-4 toxicities during alemtuzumab therapy were infections and neutropenia with one potentially treatment-related death. Complete responses were seen in 58.5 %, partial responses in 2.4 % and 29.3 % had progressive disease. After a median observation time of 46 months, 19 patients have died, 16 of them due to lymphoma and/or salvage therapy complications. Event-free and overall survival at 3 years in the whole intent to treat population are 32.3 and 62.5 %, respectively, and 42.4 and 75.1 % in the patients who received alemtuzumab. In conclusion, application of a short course of alemtuzumab after CHO(E)P-14 induction is feasible although complicated by severe infections. A current phase III trial, applying alemtuzumab as part of the initial chemotherapy protocol to avoid early progression, will further clarify its significance for the therapeutic outcome.
authors: Department of Haematology and Oncology, Göttingen Comprehensive Cancer Center (G-CCC), Georg-August-University, 37099, Goettingen, Germany.
authors: C
authors: C
authors: Binder
authors: M
authors: M
authors: Ziepert
authors: M
authors: M
authors: Pfreundschuh
authors: U
authors: U
authors: Dührsen
authors: H
authors: H
authors: Eimermacher
authors: A
authors: A
authors: Aldaoud
authors: A
authors: A
authors: Rosenwald
authors: M
authors: M
authors: Loeffler
authors: N
authors: N
authors: Schmitz
authors: L
authors: L
authors: Truemper
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
references: Blood. 2007 Oct 1;110(7):2316-23
references: 17581918
references: Blood. 2010 Nov 4;116(18):3418-25
references: 20660290
references: Curr Hematol Malig Rep. 2011 Dec;6(4):222-30
references: 21953415
references: Eur J Haematol. 2007 Jul;79(1):32-8
references: 17598836
references: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references: 18626005
references: Ann Oncol. 2009 Dec;20(12):1977-84
references: 19570965
references: Ann Oncol. 2011 Jul;22(7):1595-1600
references: 21212158
references: N Engl J Med. 1993 Sep 30;329(14):987-94
references: 8141877
references: Blood. 2011 Mar 24;117(12):3402-8
references: 21270441
references: Blood. 2003 Jun 1;101(11):4267-72
references: 12543862
references: Leuk Res. 1998 Feb;22(2):185-91
references: 9593475
references: Blood. 2011 Jun 23;117(25):6756-67
references: 21493798
references: J Clin Oncol. 1999 Apr;17(4):1244
references: 10561185
references: Haematologica. 2005 May;90(5):702-3
references: 15921394
references: Ann Oncol. 2004 Dec;15(12):1790-7
references: 15550584
references: Invest New Drugs. 2012 Feb;30(1):368-75
references: 20734108
references: J Clin Oncol. 2009 Jan 1;27(1):106-13
references: 19029417
references: J Clin Exp Hematop. 2011;51(1):29-35
references: 21628858
references: Blood. 1998 Jul 1;92(1):76-82
references: 9639502
references: J Clin Oncol. 2002 May 15;20(10):2472-9
references: 12011124
references: Br J Haematol. 2010 Oct;151(2):159-66
references: 20738307
references: Haematologica. 2007 Apr;92(4):566-7
references: 17488672
references: Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34
references: 17406867
references: J Clin Oncol. 2012 Sep 1;30(25):3093-9
references: 22851556
references: Med Oncol. 2006;23(1):17-22
references: 16645226
references: Leukemia. 2006 Sep;20(9):1533-8
references: 16871285
references: Blood. 2004 Apr 15;103(8):2920-4
references: 15070664
references: Ann Oncol. 2003 Jun;14(6):881-93
references: 12796026
references: J Clin Oncol. 2008 Jan 10;26(2):218-24
references: 18182664
references: Leuk Lymphoma. 2010 Mar;51(3):447-55
references: 20141439